Varicella Zoster Viral Retinitis following Chimeric Antigenic Response T-cell Therapy for B-cell Lymphoma

Waleed K. Alsarhania Department of Ophthalmology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia;b Department of Ophthalmology, King Saud University, Riyadh, Saudi ArabiaView further author information

, , MD &

Ahmed M. Abu El-Asrarb Department of Ophthalmology, King Saud University, Riyadh, Saudi Arabia;c Dr. Nasser Al-Rashid Research Chair in Ophthalmology, College of Medicine and Medical City, King Saud University, Riyadh, Saudi ArabiaCorrespondence[email protected]
View further author information

, , MD, PhD

References

June CH, O’Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365. doi:10.1126/science.aar6711.
PubMed Web of Science ®Google Scholar
June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64–73. doi:10.1056/NEJMra1706169.
PubMed Web of Science ®Google Scholar
Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018;131(1):121–130. doi:10.1182/blood-2017-07-793760.
PubMed Web of Science ®Google Scholar
Wudhikarn K, Palomba ML, Pennisi M, et al. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J. 2020;10(8):79. doi:10.1038/s41408-020-00346-7.
PubMed Web of Science ®Google Scholar
Long B, Brém E. Oncologic Emergencies: KA. Immune-based cancer therapies and complications. West J Emerg Med. 2020;21(3):566–580. doi:10.5811/westjem.2020.1.45898.
PubMed Web of Science ®Google Scholar
Fried S, Avigdor A, Bielorai B, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019;54(10):1643–1650. doi:10.1038/s41409-019-0487-3.
PubMed Web of Science ®Google Scholar
Los-Arcos I, Iacoboni G, Aguilar-Guisado M, et al. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection. 2020;1–17. doi:10.1007/s15010-020-01521-5. Epub ahead of print.
Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Varicella Zoster Viral Retinitis following Chimeric Antigenic Response T-cell Therapy for B-cell Lymphoma

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Varicella Zoster Viral Retinitis following Chimeric Antigenic Response T-cell Therapy for B-cell Lymphoma

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date